Results 31 to 40 of about 99,677 (264)
Case Reports in Immunology, 2016 Tocilizumab is an interleukin-6 receptor inhibitor licensed for moderate to severe rheumatoid arthritis (RA). We report a case of Tocilizumab monotherapy for severe active RA in a patient with coexisting ulcerative colitis (UC).
Matthew Chak Hin Szeto +3 more
doaj +1 more source
International Journal of Infectious Diseases, 2021 Objectives: The purpose of this study is to evaluate clinical outcomes in patients with critical COVID-19 pneumonia requiring invasive mechanical ventilation who were treated with tocilizumab Design: Single-center retrospective cohort study Setting ...
Matthew J. Fisher +4 more
doaj +1 more source
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy [PDF]
, 2015 Objective: To evaluate associations between lipid levels, inflammation, and rheumatoid arthritis (RA) disease activity, at baseline and during treatment, with the risk of major adverse cardiovascular events (MACE) in tocilizumab‐treated patients with RA.
Bathon, Joan M. +7 more
core +1 more source
Repurposing Interleukin-6 Inhibitors to Combat COVID-19. [PDF]
, 2020 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a pandemic with major implications across the world. One of the most frequent causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus disease 2019 (COVID-19), which is associated
Kato, Shumei, Kurzrock, Razelle
core +1 more source
Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis [PDF]
, 2017 Objectives Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes.
Caslake, Muriel +6 more
core +1 more source
Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction
Open Heart, 2021 Objective Beyond reducing inflammation and troponin T (TnT) release, the interleukin-6 receptor antagonist tocilizumab reduces neutrophil counts in patients with non-ST segment elevation myocardial infarction (NSTEMI). It is unclear if this is related to
Thor Ueland +10 more
doaj +1 more source
Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic in a global comparative observational study [PDF]
, 2017 Objective To compare clinical effectiveness between tocilizumab and tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) and inadequate response to conventional synthetic disease-modifying antirheumatic drugs initiating ...
Aassi, Maher +4 more
core +3 more sources
International Journal of Infectious Diseases, 2023 Objectives: Interleukin (IL)-6 inhibitors are administered to treat patients hospitalized with COVID-19. In 2021, due to shortages, different dosing regimens of tocilizumab, and a switch to sarilumab, were consecutively implemented. Using real-world data,
Maaike C. Swets +12 more
doaj +1 more source
Tocilizumab does not block interleukin-6 (IL-6) signaling in murine cells.
PLoS ONE, 2020 Tocilizumab is a humanized monoclonal antibody that is approved for the treatment of different human inflammatory diseases, including rheumatoid arthritis and cytokine release syndrome.
Juliane Lokau +7 more
doaj +1 more source
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
RMD Open, 2023 Objectives In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.Methods We conducted a retrospective multicentre study in referral centres ...
Patrice Cacoub +56 more
doaj +1 more source